Similar experiments on CLL cell lines showed some additive effect of the Bcl‐xL inhibitor when combined with trametinib + venetoclax (Fig. S2c, dark pink line), while the Mcl‐1 inhibitor was ineffective in this model (Fig. S2c). The gene discussed is BCL2L1; the disease is B-cell chronic lymphocytic leukemia.